MedPath

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 ...

Vera Therapeutics completed early enrollment for ORIGIN 3 trial of atacicept in IgAN, with 200 participants for 36-week UPCR primary endpoint. Topline results expected Q2 2025, and 96-week data from ORIGIN Phase 2b trial to be presented Q4 2024.


Reference News

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 ...

Vera Therapeutics completed early enrollment for ORIGIN 3 trial of atacicept in IgAN, with 200 participants for 36-week UPCR primary endpoint. Topline results expected Q2 2025, and 96-week data from ORIGIN Phase 2b trial to be presented Q4 2024.

© Copyright 2025. All Rights Reserved by MedPath